MOTS-c: Evidence, Trials & Why It's Banned in Sport

Common contexts

• Clinics may reference this peptide within broader wellness or longevity pathways.
• Use this directory page to compare profile transparency and consultation options.

Safety information

• This directory is informational and does not provide medical advice.
• Always discuss suitability and risk profile directly with a licensed clinician.

Clear intro

MOTS-c sits at peak hype: a genuinely interesting molecule with real preclinical science, no completed human administration trials, and an explicit WADA ban. Pages that hold all three facts at once are rare — which is the opportunity.

Who this is for

This page is for people researching longevity and metabolic peptides who want the actual evidence state — and for athletes who need to know it is explicitly banned.

What to ask before choosing a clinic

• No completed human trials of MOTS-c exist — what is the basis for recommending it to me?
• Am I subject to any sports testing? If so, why are we discussing a WADA-prohibited substance?
• What approved, evidence-based options address my metabolic goals first?

Pricing and red flags

Grey-market pricing for an unproven compound. If a clinic quotes a MOTS-c programme price, the evidence questions above matter more than the number.

• Claims of proven fat-loss, endurance, or longevity benefits in humans — that evidence does not exist yet.
• No mention of the explicit WADA ban to athletic clients.
• Framing FDA compounding-committee review as approval.

What is MOTS-c?

MOTS-c (mitochondrial open reading frame of the twelve S rRNA type-c) is a peptide encoded within mitochondrial DNA rather than the nuclear genome — part of a class called mitochondrial-derived peptides. Since its 2015 discovery it has been studied for roles in metabolic regulation, insulin sensitivity, and exercise adaptation, mostly in cells and animals. It is not an approved medicine anywhere; early-phase human trials of related compounds and of MOTS-c biology are ongoing, but no completed human trial of administering unmodified MOTS-c had been published as of mid-2026. It drew unusual regulatory attention in the other direction: WADA explicitly named it on the prohibited list from January 2024.

How it works

MOTS-c is thought to act on AMPK signalling — a central regulator of cellular energy — which is the basis for claims about metabolic health, exercise performance, and longevity. That mechanism is real in laboratory settings; what does not yet exist is completed human trial evidence that injecting the peptide produces those benefits in people. The gap between the mechanism and the marketing is the entire story of this peptide so far.

Cost overview

With no approved product and no completed human efficacy trials, any price is a grey-market price for an unproven compound. The question is not cost but whether the purchase makes sense at all yet. See the peptide therapy cost guide.

What to expect from clinics

• A credible provider should say plainly that no completed human trials of MOTS-c administration exist.
• Expect a clear statement that it is WADA-banned at all times — any tested athlete must avoid it.
• Be cautious of 'mitochondrial optimisation' framing that implies proven human benefit.

Safety considerations

Because no completed human administration trials exist, MOTS-c's efficacy and safety in people are simply unknown — dosing, long-term effects, and risks are extrapolated from preclinical work. Grey-market products add unverified identity and purity on top. Tested athletes face strict-liability anti-doping consequences. This page does not recommend MOTS-c and does not provide dosing or administration guidance.

Compare this with semaglutide vs tirzepatide or move into city pages such as Los Angeles and New York if you want to compare how providers frame these treatments locally.